000303360 001__ 303360
000303360 005__ 20250804114347.0
000303360 0247_ $$2doi$$a10.1038/s41698-025-01064-8
000303360 0247_ $$2pmid$$apmid:40751074
000303360 0247_ $$2pmc$$apmc:PMC12317078
000303360 037__ $$aDKFZ-2025-01610
000303360 041__ $$aEnglish
000303360 082__ $$a610
000303360 1001_ $$aRong, Chao$$b0
000303360 245__ $$aIntegrative bioinformatics analysis and experimental validation identify CHEK1 as an unfavorable prognostic biomarker related to immunosuppressive phenotypes in soft tissue sarcomas.
000303360 260__ $$a[London]$$bSpringer Nature$$c2025
000303360 3367_ $$2DRIVER$$aarticle
000303360 3367_ $$2DataCite$$aOutput Types/Journal article
000303360 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754299940_1784
000303360 3367_ $$2BibTeX$$aARTICLE
000303360 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303360 3367_ $$00$$2EndNote$$aJournal Article
000303360 520__ $$aSoft tissue sarcomas (STS), including rhabdomyosarcoma (RMS), exhibit significant heterogeneity and limited responsiveness to immune checkpoint blockade (ICB). Unsupervised tumor immune phenotype based on multi-omics expression profiling of STS has been less studied. To reveal the tumor immune phenotype of STS and identify promising therapeutic targets, multi-omics expression profiling across various subtypes of STS was investigated. Here, we established a novel molecular classifier based on immune cell subsets related to TGFβ1 and IFNγ to identify distinct immune phenotypes with higher or lower cytotoxic contents. Immune-high clusters demonstrated enriched immune cell infiltration, elevated IFNγ-related signatures, and favorable clinical outcomes. In contrast, immune-low clusters were enriched for immunosuppressive cell types and exhibited poor survival. CHEK1 emerged as a key node associated with immunosuppressive phenotypes and was significantly overexpressed in immune-low tumors. In situ analysis of independent validation cohorts revealed the significant correlation between CHEK1 and tumor-infiltrating immune cells. Collectively, our findings establish a novel risk assessment strategy for RMS and STS patients, and highlight the potential of CHEK1 as a promising therapeutic target in combination with immune checkpoint inhibitor therapy.
000303360 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000303360 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303360 7001_ $$aLiu, Yun$$b1
000303360 7001_ $$aXiang, Fang$$b2
000303360 7001_ $$aZhao, Xin$$b3
000303360 7001_ $$aZhang, Jinjin$$b4
000303360 7001_ $$aXiao, Zuorun$$b5
000303360 7001_ $$aWang, Jinsha$$b6
000303360 7001_ $$aChen, Lin$$b7
000303360 7001_ $$aGuo, Zhiqi$$b8
000303360 7001_ $$aZhang, Ziyu$$b9
000303360 7001_ $$aAn, Jingnan$$b10
000303360 7001_ $$aShen, Jing$$b11
000303360 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b12$$udkfz
000303360 7001_ $$aYuan, Xiaodong$$b13
000303360 7001_ $$aZhang, Qiong$$b14
000303360 7001_ $$aWang, Shouli$$b15
000303360 773__ $$0PERI:(DE-600)2891458-2$$a10.1038/s41698-025-01064-8$$gVol. 9, no. 1, p. 268$$n1$$p268$$tnpj precision oncology$$v9$$x2397-768X$$y2025
000303360 909CO $$ooai:inrepo02.dkfz.de:303360$$pVDB
000303360 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000303360 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000303360 9141_ $$y2025
000303360 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PRECIS ONCOL : 2022$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:43:48Z
000303360 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:43:48Z
000303360 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:43:48Z
000303360 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-04-10T15:43:48Z
000303360 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PRECIS ONCOL : 2022$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-30
000303360 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-30
000303360 9201_ $$0I:(DE-He78)E221-20160331$$kE221$$lMolekulare Grundlagen von HNO-Tumoren$$x0
000303360 980__ $$ajournal
000303360 980__ $$aVDB
000303360 980__ $$aI:(DE-He78)E221-20160331
000303360 980__ $$aUNRESTRICTED